英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
beriah查看　beriah　在百度字典中的解释百度英翻中〔查看〕
beriah查看　beriah　在Google字典中的解释Google英翻中〔查看〕
beriah查看　beriah　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Rechallenge therapy versus tyrosine kinase inhibitor (TKI) for advanced . . .
    Currently, the standard third-line treatment options for advanced metastatic colorectal cancer (mCRC) include regorafenib, fruquintinib, and trifluridine tipiracil (TAS-102), but these drugs have
  • Current Targeted Therapy for Metastatic Colorectal Cancer
    Abstract Colorectal cancer (CRC) is the third most common type of cancer and the second leading cause of cancer deaths worldwide Surgery or surgery plus radiotherapy and or chemotherapy for patients with metastatic CRC (mCRC) were accepted as the main therapeutic strategies until the early 2000s, when targeted drugs, like cetuximab and bevacizumab, were developed
  • Current advances in targeted therapy for metastatic colorectal cancer . . .
    Schematic diagram of actionable therapeutic targets and selected targeted agents for the treatment of metastatic colorectal cancer TKI = tyrosine kinase is an ongoing phase III study comparing XL092 (TKI targeting MET, VEGFR2, AXL and MERA) in combination with atezolizumab against regorafenib in pre-treated mCRC While these studies
  • Zanzalintinib Atezolizumab Improves CRC Survival, Expands TKIs Role in . . .
    Promising new data from the phase 3 STELLAR-303 pivotal trial (NCT05425940) indicate that zanzalintinib (XL092) in combination with atezolizumab (Tecentriq) significantly improved overall survival (OS) compared with regorafenib (Stivarga) in patients with previously treated metastatic colorectal cancer (CRC) 1 This marks a critical advancement in the clinical development program for
  • Treatment of Metastatic Colorectal Cancer: ASCO Guideline
    Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide 1 Almost 150,000 new cases and more than 50,000 deaths from CRC are reported each year in the United States 2 In recent decades, the overall incidence of CRC has decreased among older adults because of screening and lifestyle factors; however, at the same time, incidence is increasing among younger adults 3
  • Emerging tyrosine kinase inhibitors for the treatment of metastatic . . .
    Over the last decade, the addition of antibodies that block the epidermal growth factor receptor (EGFR) or angiogenesis to the classic chemotherapy backbone has improved overall survival in metastatic colorectal cancer (mCRC) However, the role of the other major targeted therapy, the tyrosine kinase inhibitors (TKIs), is not yet fully clarified
  • (PDF) Rechallenge therapy versus tyrosine kinase inhibitor (TKI) for . . .
    PDF | Currently, the standard third-line treatment options for advanced metastatic colorectal cancer (mCRC) include regorafenib, fruquintinib, and | Find, read and cite all the research you
  • Combination IO TKI Strategies in Metastatic Colorectal Cancer - OncLive
    A comprehensive review on combination strategies with immune checkpoint and tyrosine kinase inhibitors in patients with metastatic colorectal cancer EP: 1 Overview of Molecular Testing in
  • Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment
    The global metastatic colorectal cancer market is expected to reach $9 78 billion by 2034 This is a huge market opportunity for sure and the focus will be to target non-microsatellite instability
  • Lost in translation: Revisiting the use of tyrosine kinase inhibitors . . .
    Colorectal cancer (CRC) is the 4th most lethal cancer in the world approximately causing 900,000 deaths every year Recent advances in treatment options including surgery, radiotherapy, chemotherapy, and targeted therapy—along with early diagnosis—have improved the overall survival (OS) rate of patients with CRC [1] In the cases of metastatic disease, fluoropyrimidine with either





中文字典-英文字典  2005-2009